Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
His6-ZTaq-GS-Cys-DOTA-68Ga
- Development stage
- Unknown
- Lead developer
- Affibody
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
His6-ZTaq-GS-Cys-DOTA-68Ga is a Gallium-68 (68Ga) radiolabeled affibody conjugate used as a non-specific negative control in preclinical positron emission tomography (PET) imaging studies. The molecule consists of a hexahistidine-tagged (His6) affibody (ZTaq) that specifically binds to Taq DNA polymerase (a non-mammalian protein), a glycine-serine (GS) linker, a C-terminal cysteine (Cys) residue, and the chelator DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) complexed with the positron emitter 68Ga. Because Taq DNA polymerase is not naturally present in mammalian tissues, His6-ZTaq-GS-Cys-DOTA-68Ga does not exhibit specific binding in vivo, making it an ideal control for assessing non-specific uptake, background signal, and biodistribution of target-specific affibody-based PET tracers (such as those targeting HER2 or HER3) in tumor-bearing mouse models.
- Other names
- 68Ga-DOTA-His6-ZTaq-Cys68Ga-DOTA-ZTaqnon-HER2-specific Affibody moleculenon-HER-2-specific Affibody moleculenon-HER 2-specific Affibody molecule
Beyond the preview
Go deeper on His6-ZTaq-GS-Cys-DOTA-68Ga.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on His6-ZTaq-GS-Cys-DOTA-68Ga.